Evox Therapeutics

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Sigma-Aldrich announces death of chairman and ceo Dr Jai Nagarkatti joined the US firm in 1976
  3. Novartis obtains FDA approval for CML drug, Scemblix The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
  4. Merck bolsters its ADC CDMO offering with €71m Missouri manufacturing site expansion The facility's expansion has tripled its ADC manufacturing capacity, bolstering Merck's CDMO offering for current and new clients
  5. Picking a CDMO as a CGT developer: what to consider and why Cell and gene therapy development and manufacture can be risky and highly complex, so biopharma companies would benefit from investing in a reliable and experienced CDMO

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Drug Delivery

Evox announces collaboration to work on AAV vectors as novel gene technology

Evox has entered into a research collaboration for developing exosome-encapsulated AAV (exoAAV) vectors with the Icahn School of Medicine at Mount Sinai in New York
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Recruitment

Evox hires two experienced new VPs

Bo Kara will take over VP of Process Development and Simon Dew will be VP of Business Development
Finance

Research funding round-up

Capital to support the development of new drugs and technology around the world
Research & Development

Evox Therapeutics to expand its work on cell-targeted delivery of nucleic acid-based drugs

Funding received from the Bill & Melinda Gates Foundation
Finance

Evox Therapeutics wins funding to explore exosome-mediated delivery of dystrophin

Targeted delivery of dystrophin has the potential to be a highly effective treatment for Duchenne muscular dystrophy
Research & Development

Evox expands exosome platform for drug delivery

The therapeutics company has rasied £35.5 million of new capital to fund the project
Subscribe now